Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells

Blood

Volumn 103, Issue 3, 2004, Pages 955-962

  Prager, Gerald W ^a   Breuss, Johannes M ^a   Steurer, Stefan ^a   Mihaly, Judit ^a   Binder, Bernd R ^a  

^a Dept of Vasc Biol/Thromb Res ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CELL RECEPTOR; GELATINASE A; INTEGRIN; PLASMIN; PROUROKINASE; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; CAPILLARY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION;

EID: 1642459357     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2214     Document Type: Article

References (33)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.
2. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001;21:1104-1117.
3. Stoppelli MP, Tacchetti C, Cubellis MV, et al. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell. 1986;45:675-684.
4. Koshelnick Y, Ehart M, Stockinger H, Binder BR. Mechanisms of signaling through urokinase receptor and the cellular response. Thromb Haemost. 1999;82:305-311.
5. Murphy G, Stanton H, Cowell S, et al. Mechanisms for pro matrix metalloproteinase activation. APMIS. 1999;107:38-44.
6. Binder BR. Influence of urokinase on cell proliferation and invasion. Blood Coagul Fibrinolysis. 1990;1:717-720.
7. Kobayashi H, Schmitt M, Goretzki L, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem. 1991;266:5147-5152.
8. Orgel D, Schroder W, Hecker-Kia A, et al. The cleavage of pro-urokinase type plasminogen activator by stromelysin-1. Clin Chem Lab Med. 1998;36:697-702.
9. Ellerbroek SM, Fishman DA, Kearns AS, Bafetti LM, Stack MS. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res. 1999;59:1635-1641.
10. Mechtcheriakova D, Schabbauer G, Lucerna M, et al. Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J. 2001;15:230-242.
11. Huber J, Bochkov VN, Binder BR, Leitinger N. The isoprostane 8-iso-PGE(2) stimulates endothelial cells to bind monocytes via cyclic AMP- and p38 MAP kinase-dependent signaling pathways. Antioxid Redox Signal. 2003;5:163-169.
12. Krebs M, Kaun C, Lorenz M, et al, Protease dependent activation of endothelial cells by peritoneal dialysis effluents. Thromb Haemost. 1999;82:1334-1341.
13. Luque A, Gomez M, Puzon W, et al. Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J Biol Chem. 1996;271:11067-11075.
14. Faull RJ, Kovach NL, Harlan JM, Ginsberg MH. Affinity modulation of integrin alpha 5 beta 1: regulation of the functional response by soluble fibronectin. J Cell Biol. 1993;121:155-162.
15. Dzamba BJ, Bultmann H, Akiyama SK, Peters DM. Substrate-specific binding of the amino terminus of fibronectin to an integrin complex in focal adhesions. J Biol Chem. 1994;269:19646-19652.
16. Eijnden-Schrauwen Y, Atsma DE, Lupu F, et al. Involvement of calcium and G proteins in the acute release of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:2177-2187.
17. Wolf BB, Vasudevan J, Henkin J, Gonias SL, Nerve growth factor-gamma activates soluble and receptor-bound single chain urokinase-type plasminogen activator. J Biol Chem. 1993;268:16327-16331.
18. Babaei S, Stewart DJ. Overexpression of endothelial NO synthase induces angiogenesis in a co-culture model. Cardiovasc Res. 2002;55:190-200.
19. Cooke ED, Bowcock SA, Pilcher MF, et al. Serum fibrin(ogen) degradation products in diagnosis of deep-vein thrombosis and pulmonary embolism after hip surgery. Lancet. 1975;2:51-54.
20. Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell. 1992;71:411-421.
21. Ellerbroek SM, Wu YI, Overall CM, Stack MS. Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J Biol Chem. 2001;276:24833-24842.
22. Giles FJ. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist. 2001;6(suppl 5):32-39.
23. Podar K, Tai YT, Lin BK, et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem. 2002;277:7875-7881.
24. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994;370:61-65.
25. Strongin AY, Marmer BL, Grant GA, Goldberg GI. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J Biol Chem. 1993;268:14033-14039.
26. Teti A, Farina AR, Villanova I, et al. Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. Int J Cancer. 1998;77:82-93.
27. Zigrino P, Drescher C, Mauch C. Collagen-induced proMMP-2 activation by MT1-MMP in human dermal fibroblasts and the possible role of alpha2beta1 integrins. Eur J Cell Biol. 2001;80:68-77.
28. Yan L, Moses MA, Huang S, Ingber DE. Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells. J Cell Sci. 2000;113(pt 22):3979-3987.
29. Takagi J, Petre B, Walz T, Springer T. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002;110:599-611.
30. Kroon ME, Koolwijk P, van Goor H, et al. Role and localization of urekinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol. 1999;154:1731-1742.
31. Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996;56:2428-2433.
32. Plesner T, Ploug M, Ellis V, et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood, 1994;83:808-815.
33. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci U S A. 2001;98:119-124.